Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Aimovig (erenumab by Year
Aimovig (erenumab — migraine prevention Migraine) ($M)
Novartis Aimovig (erenumab: $335M in FY2025, up 7.4% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
335
Period ended Dec 31, 2025
Change on a year earlier
+7.4%
312 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Aimovig | 335 | 312 | 7 | 3”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Aimovig (erenumab — migraine prevention Migraine) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 335 | +7.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 312 | +17.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 266 | +22.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 218 | +1.4% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 215 | +31.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 164 | +59.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 103 | +1,187.5% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 8 | – | Novartis Form 6-K (0001370368-20-000007) ↗ |
Breakdown
What makes up aimovig (erenumab
Cite this data
StockData. (2026). Novartis Aimovig (erenumab ($M), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-aimovig
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.